Sign in
NGNE Stock Price, Chart, Stats & News
Neurogene Inc.
Save
480.54M
Market cap
–
Current P/E
–
Forward P/E
NGNE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -31.24% |
ROE | -32.99% |
D/E | 0.04x |
Interest coverage ratio | -20665.40x |
NGNE valuation
P/E | – |
P/S | – |
P/B | 1.19x |
P/CF | -4.12x |
P/FCF | -4.08x |
P/OCF | -4.12x |
PEG | 0.53x |
EV multiple | -4.56x |
About
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Similar securities
Based on sector and market capitalization
Report issue